NOV 28, 2016 11:07 AM PST

Cancer Drug May be Repurposed to Treat Muscular Dystrophy

A cancer drug that’s approved for the treatment of kidney cancer may also be effective against a form of muscular dystrophy.

Sunitinib is a small-molecule drug that inhibits receptor tyrosine kinases (RTK). It was approved by the FDA for the treatment of renal cell carcinoma and a form of gastrointestinal tumor in 2006. Now, researchers at the King’s College London say the mechanism behind this drug may also act to improve muscle strength in patients with facioscapulohumeral dystrophy (FSHD).
FSHD is a genetically inherited form of muscular dystrophy that primarily affects the muscles around the face, shoulders, and upper arms. Patients with this condition experience progressive muscle wasting that starts in early childhood. The muscle weakness can severely impair mobility, speaking, and even breathing.
"Muscle dystrophies are an untreatable collection of diseases that result in progressive loss of mobility and often premature death, and affect millions of people worldwide,” said Robert Knight, Principal Investigator at the Division of Craniofacial Development and Stem Cell Biology at King’s College London’s Dental Institute, and the study’s co-lead author.
In studying muscle biology, researchers noted that a receptor tyrosine kinase Rearranged during transfection (RET) seemed to be upregulated in muscle stem cells that express the DUX4 protein. In FSHD, the genomic region controlling DUX4 appears to be abnormally activated (due to hypomethylation). This, in turn, overstimulates the production and activity of DUX4, which seems to contribute to the muscle weakness characteristic of FSHD.
Could an RTK inhibitor reverse this effect? This was the researcher’s main hypothesis, and they tested it first by confirming that overexpression of DUX4 in mice led to upregulation of RET. Furthermore, administration of sunitinib, an RTK inhibitor, suppressed RET activity and reduced damage to muscle cells.

“Specifically, blocking DUX4-mediated RET signaling increases myogenic differentiation, giving further insight into the molecular pathology of DUX4 and highlighting RET signaling as potential drug target," the authors explain.
The drug shows promise in improving muscle strength for patients afflicted with FSHD. And since the drug is already approved, repurposing it for the treatment of FSHD may take much less time, assuming further studies also find the same promising results.
“The discovery that an approved anticancer treatment may prove useful for enhancing the ability of stem cells to repair muscle in a type of muscle dystrophy affecting face and shoulder muscles offers a new route for putative therapies for many patients,” said Knight.

Additional sources: King's College London press release, MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at
You May Also Like
DEC 09, 2019
DEC 09, 2019
Hair dyes associated with increased risk of breast cancer
Research recently published in the International Journal of Cancer suggests that certain hair dyes and chemical relaxants are associated with breast cancer...
JAN 15, 2020
Clinical & Molecular DX
JAN 15, 2020
Laser microchip picks up cancer markers in urine
A future where patients no longer need to endure expensive, painful and complicated cancer tests could soon become a reality. Researchers have developed a...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Acid-Reflux Drugs May Negatively Impact Breast Cancer Survivors
Many of us have taken some form of an acid-reflux drug—especially after a meal that causes discomfort. However, now researchers are indicating that s...
JAN 20, 2020
JAN 20, 2020
Did you know these non-cancer drugs can also fight cancer?
A study from MIT. Harvard and the Dana-Farber Cancer Institute has concluded that almost 50 existing non-oncological drugs have anti-cancer properties capa...
FEB 04, 2020
Health & Medicine
FEB 04, 2020
World Health Organization Outlines Strategy to Eradicate Cervical Cancer
Today—World Cancer Day—the World Health Organization (WHO) announced a draft of a global strategy to eliminate cervical cancer as a public heal...
FEB 10, 2020
FEB 10, 2020
How Cancer Evades the Immune System Time and Time Again
Scientists discovered a new mechanism by which cancer cells evade the immune system to further their own agenda: invade, multiply, and spread. Identifying...
Loading Comments...